| Literature DB >> 31736765 |
Xiaolang Tian1, Changwu Huang1, Xiaoli Ye1, Hongyan Jiang1, Rufang Zhang1, Xiaofang Hu1, Dongshuang Xu1.
Abstract
Background: The increasing prevalence of extensively drug-resistant Klebsiella pneumoniae (XDR-KP) poses a serious threat to clinical anti-infective treatment. This retrospective study assessed the molecular epidemiology of and risk factors for infections with XDR-KP to investigate the mechanism of drug resistance and the epidemiological characteristics.Entities:
Keywords: MLST; extensively drug-resistant Klebsiella pneumoniae; molecular epidemiology; mortality; risk factors
Year: 2019 PMID: 31736765 PMCID: PMC6838015 DOI: 10.3389/fphar.2019.01307
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
The antimicrobial susceptibility of extensively drug-resistant Klebsiella pneumoniae (XDR-KP) and non-XDR-KP.
| Antibiotics | XDR-KP (n = 69) | non-XDR-KP (n = 138) | |||||
|---|---|---|---|---|---|---|---|
| S | I | R | S | I | R | ||
| Ampicillin | 0 (0) | 0 (0) | 69 (100) | 15 (10.9) | 4 (2.9) | 119 (86.2) | |
| Ampicillin/sulbactam | 0 (0) | 0 (0) | 69 (100) | 70 (50.8) | 2 (1.4) | 66 (47.8) | |
| Piperacillin | 0 (0) | 0 (0) | 69 (100) | 77 (55.8) | 8 (5.8) | 53 (38.4) | |
| Cefazolin | 0 (0) | 0 (0) | 69 (100) | 55 (39.9) | 5 (3.6) | 78 (56.5) | |
| Ceftriaxone | 0 (0) | 0 (0) | 69 (100) | 93 (67.4) | 3 (2.2) | 42 (30.4) | |
| Ceftazidime | 0 (0) | 0 (0) | 69 (100) | 94 (68.1) | 4 (2.9) | 40 (29.0) | |
| Cefepime | 0 (0) | 0 (0) | 69 (100) | 104 (75.4) | 8 (5.8) | 26 (18.8) | |
| Cefoxitin | 0 (0) | 0 (0) | 69 (100) | 101 (73.2) | 5 (3.6) | 32 (23.2) | |
| Aztreonam | 0 (0) | 0 (0) | 69 (100) | 68 (49.2) | 11 (8.0) | 59 (42.8) | |
| Ciprofloxacin | 0 (0) | 0 (0) | 69 (100) | 87 (63.0) | 0 (0.0) | 51 (37.0) | |
| Levofloxacin | 0 (0) | 0 (0) | 69 (100) | 91 (65.9) | 4 (2.9) | 43 (31.2) | |
| Gentamicin | 0 (0) | 0 (0) | 69 (100) | 90 (65.2) | 7 (5.1) | 41 (29.7) | |
| Tobramycin | 0 (0) | 0 (0) | 69 (100) | 104 (75.4) | 8 (5.8) | 26 (18.8) | |
| Amikacin | 0 (0) | 0 (0) | 69 (100) | 118 (85.5) | 5 (3.6) | 15 (10.9) | |
| Ertapenem | 0 (0) | 0 (0) | 69 (100) | 126 (91.4) | 2 (1.4) | 10 (7.2) | |
| Imipenem | 0 (0) | 0 (0) | 69 (100) | 129 (93.5) | 0 (0) | 9 (6.5) | |
| Meropenem | 0 (0) | 0 (0) | 69 (100) | 129 (93.5) | 0 (0) | 9 (6.5) | |
| Tigecycline | 69 (100) | 0 (0) | 0 (0) | 138 (100) | 0 (0) | 0 (0) | |
| Polymyxin B | 69 (100) | 0 (0) | 0 (0) | 138 (100) | 0 (0) | 0 (0) | |
Values are presented as n (%), unless otherwise noted. S, susceptible; I, intermediate-resistant; R, resistant. “–” indicates data not available. Bold face indicates values that are significant (P < 0.05).
Distribution of resistance genes and MLST types of extensively drug-resistant Klebsiella pneumoniae (XDR-KP).
| Microorganism(no. of strains) | Resistance genes and MLST types (no. of strains) | ST types | ||||
|---|---|---|---|---|---|---|
| Carbapenemase resistance genes | ESBL resistance genes | AmpC resistance genes | Quinolone resistance determinants | Aminoglycoside resistance determinants | ||
| XDR-KP (69) | ST11 (58) | |||||
| ST20 (5) | ||||||
| ST45 (1) | ||||||
| ST592 (2) | ||||||
| ST661 (2) | ||||||
| ST751 (1) | ||||||
MLST, multilocus sequence typing; ESBL, extended-spectrum β-lactamase.
Univariate analysis of risk factors for infection with extensively drug-resistant Klebsiella pneumoniae (XDR-KP) and non-XDR-KP.
| Variables | XDR-KP infection (n = 69) | Control group (n = 138) | OR (95% CI) | |
|---|---|---|---|---|
| Male gender | 37 (53.6) | 72 (52.2) | 1.06 (0.59–1.89) | 0.844 |
| Elderly | 31 (44.9) | 58 (42.0) | 1.13 (0.63–2.02) | 0.691 |
| ICU admission | 37 (53.6) | 33 (23.9) | 3.68 (1.99–6.79) | |
| Transferring from another hospital | 26 (37.7) | 33 (23.9) | 1.92 (1.03–3.59) | |
| Hypertension | 25 (36.2) | 36 (26.1) | 1.61 (0.87–2.99) | 0.131 |
| Diabetes | 18 (26.1) | 27 (19.6) | 1.45 (0.73–2.87) | 0.284 |
| Hypoproteinemia | 18 (26.1) | 32 (23.2) | 1.16 (0.60–2.27) | 0.646 |
| Hypokalemia | 15 (21.7) | 18 (13.0) | 1.85 (0.87–3.95) | 0.107 |
| Severe anemia | 4 (5.8) | 9 (6.5) | 0.88 (0.26–2.97) | 0.839 |
| Septic shock | 18 (26.1) | 22 (15.9) | 1.86 (0.92–3.77) | 0.081 |
| Solid tumors | 23 (33.3) | 38 (27.5) | 1.32 (0.71–2.46) | 0.388 |
| Respiratory diseases | 25 (36.2) | 31 (22.5) | 1.96 (1.04–3.69) | |
| Liver diseases | 19 (27.5) | 34 (24.6) | 1.16 (0.60–2.24) | 0.652 |
| Gastrointestinal diseases | 15 (21.7) | 28 (20.3) | 1.09 (0.54–2.21) | 0.809 |
| Cardiovascular diseases | 10 (14.5) | 12 (8.7) | 1.78 (0.73–4.35) | 0.202 |
| Renal diseases | 15 (21.7) | 35 (25.4) | 0.82 (0.41–1.63) | 0.566 |
| Endocrine system diseases | 6 (8.7) | 20 (14.5) | 0.56 (0.21–1.47) | 0.235 |
| Pulmonary infection | 16 (23.2) | 17 (12.3) | 2.15 (1.01–4.57) | |
| Intra-abdominal infection | 9 (13.0) | 16 (11.6) | 1.14 (0.48–2.74) | 0.763 |
| Urinary tract infection | 10 (14.5) | 23 (16.7) | 0.85 (0.38–1.90) | 0.687 |
| Parenteral nutrition | 11 (15.9) | 15 (10.9) | 1.56 (0.67–3.59) | 0.299 |
| Mechanical ventilation | 16 (23.2) | 19 (13.8) | 1.89 (0.90–3.96) | 0.088 |
| Urinary catheter | 29 (42.0) | 51 (37.0) | 1.24 (0.69–2.23) | 0.481 |
| Tracheal cannula | 26 (37.7) | 19 (13.8) | 3.79 (1.91–7.53) | |
| Drainage tube | 8 (11.6) | 23 (16.7) | 0.66 (0.28–1.55) | 0.335 |
| Previous surgery in the past 6 months | 24 (34.8) | 38 (27.5) | 1.40 (0.76–2.61) | 0.283 |
| Central venous catheter | 10 (14.5) | 18 (13.0) | 1.13 (0.49–2.60) | 0.774 |
| Arterial catheter | 9 (13.0) | 25 (18.1) | 0.68 (0.29–1.55) | 0.353 |
| Cephalosporins | 26 (37.7) | 48 (34.8) | 1.13 (0.62–2.06) | 0.682 |
| Carbapenem | 21 (30.4) | 14 (10.1) | 3.88 (1.82–8.23) | |
| Aminoglycosides | 6 (8.7) | 20 (14.5) | 0.56 (0.22–1.47) | 0.235 |
| Quinolones | 12 (17.4) | 28 (20.3) | 0.83 (0.39–1.75) | 0.619 |
| Tetracyclines | 4 (5.8) | 6 (4.3) | 1.35 (0.37–4.97) | 0.647 |
| Macrolides | 5 (7.2) | 8 (5.8) | 1.27 (0.39–4.04) | 0.685 |
| Metronidazole | 18 (26.1) | 25 (18.1) | 1.59 (0.80–3.18) | 0.183 |
| Glycopeptides | 12 (17.4) | 11 (8.0) | 2.43 (1.01–5.84) | |
Values are presented as n (%), unless otherwise noted. Bold face indicates values that are significant (P < 0.05). “–” indicates data not available.
ICU, intensive care unit.
Multivariate analysis of risk factors for infection with extensively drug-resistant Klebsiella pneumoniae (XDR-KP) and non-XDR-KP.
| Variables | B | S.E | Wals | OR | 95% CI | |
|---|---|---|---|---|---|---|
| ICU admission | 1.19 | 0.35 | 11.60 | 3.28 | 1.66–6.49 | |
| Tracheal cannula | 1.15 | 0.39 | 8.84 | 3.16 | 1.48–6.76 | |
| Carbapenem exposure | 1.15 | 0.47 | 5.90 | 3.16 | 1.25–7.98 |
Bold face indicates values that are significant (P < 0.05). ICU, intensive care unit.
Risk factors associated with 28-day mortality.
| Variables | Nonsurvivors (n = 21) | Survivors (n = 48) | OR (95% CI) | OR (95% CI) | ||
|---|---|---|---|---|---|---|
| Elderly | 10 (47.6) | 21 (43.8) | 1.17 (0.42–3.27) | 0.766 | ||
| ICU admission | 9 (42.9) | 28 (58.3) | 0.54 (0.19–1.51) | 0.236 | ||
| Solid tumors | 14 (66.7) | 9 (18.8) | 8.67 (2.71–27.68) | 7.22 (1.84–28.34) | ||
| Respiratory diseases | 9 (42.9) | 16 (33.3) | 1.50 (0.52–4.30) | 0.449 | ||
| Digestive system disease | 7 (33.3) | 12 (25.0) | 1.50 (0.49–4.59) | 0.476 | ||
| Urinary System Diseases | 3 (14.3) | 12 (25.0) | 0.50 (0.13–1.99) | 0.321 | ||
| Cardiovascular diseases | 4 (19.0) | 6 (12.5) | 1.65 (0.41–6.58) | 0.477 | ||
| Hypoproteinemia | 8 (38.1) | 10 (20.8) | 2.34 (0.76–7.19) | 0.133 | ||
| Hypokalemia | 7 (33.3) | 8 (16.7) | 2.50 (0.77–8.16) | 0.122 | ||
| Septic shock | 11 (52.4) | 7 (14.6) | 6.44 (1.99–20.82) | 9.46 (2.00–44.72) | ||
| Parenteral nutrition | 3 (14.3) | 8 (16.7) | 0.83 (0.20–3.51) | 0.804 | ||
| Tracheal cannula | 12 (57.1) | 14 (29.2) | 3.24 (1.12–9.39) | |||
| Drainage tube | 2 (9.5) | 6 (12.5) | 0.74 (0.14–3.99) | 0.722 | ||
| Previous surgery in the past 6 months | 6 (28.6) | 18 (37.5) | 0.67 (0.22–2.03) | 0.474 | ||
| Central venous catheter | 3 (14.3) | 7 (14.6) | 0.98 (0.23–4.21) | 0.974 | ||
| Arterial catheter | 3 (14.3) | 6 (12.5) | 1.17 (0.26–5.19) | 0.839 | ||
| Mechanical ventilation | 8 (38.1) | 8 (16.7) | 4.39 (1.35–14.28) | 0.052 | ||
| Cephalosporins | 9 (42.9) | 17 (35.4) | 1.37 (0.48–3.89) | 0.557 | ||
| Carbapenem | 7 (33.3) | 14 (29.2) | 1.21 (0.40–3.65) | 0.729 | ||
| Aminoglycosides | 2 (9.5) | 4 (8.3) | 1.16 (0.20–6.87) | 0.872 | ||
| Quinolones | 4 (19.0) | 8 (16.7) | 1.18 (0.31–4.44) | 0.810 | ||
| Macrolides | 1 (4.8) | 4 (8.3) | 0.55 (0.06–5.24) | 0.599 |
Values are presented as n (%), unless otherwise noted. Bold face indicates values that are significant (P < 0.05). “–” indicates data not available.
ICU, intensive care unit.